4//SEC Filing
Smith Thomas B 4
Accession 0001103021-22-000018
CIK 0001103021other
Filed
Jan 30, 7:00 PM ET
Accepted
Jan 31, 5:58 PM ET
Size
19.3 KB
Accession
0001103021-22-000018
Insider Transaction Report
Form 4
Smith Thomas B
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2022-01-27+17,361→ 37,315 total - Exercise/Conversion
Common Stock
2022-01-31+7,548→ 44,863 total - Exercise/Conversion
Restricted Stock Units
2022-01-29−7,548→ 7,549 totalExercise: $0.00Exp: 2023-01-29→ Common Stock (7,548 underlying) - Award
Stock Options (right to buy)
2022-01-27$3.66/sh+259,186$948,621→ 259,186 totalExercise: $3.66Exp: 2032-01-26→ Common Stock (259,186 underlying) - Exercise/Conversion
Restricted Stock Units
2022-01-27−17,361→ 34,722 totalExercise: $0.00Exp: 2024-01-27→ Common Stock (17,361 underlying) - Exercise/Conversion
Restricted Stock Units
2022-01-31−7,667→ 0 totalExercise: $0.00Exp: 2022-01-31→ Common Stock (7,667 underlying) - Exercise/Conversion
Common Stock
2022-01-31+7,667→ 52,530 total - Award
Restricted Stock Units
2022-01-27+46,448→ 46,448 totalExercise: $0.00Exp: 2025-01-27→ Common Stock (46,448 underlying)
Footnotes (7)
- [F1]The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on January 27, 2022.
- [F2]The stock options were issued to the Reporting Person on January 27, 2022, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (the "Plan"). The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2023; (ii) January 27, 2024; and (iii) January 27, 2025.
- [F3]The Restricted Stock Units ("RSUs") were issued to the Reporting Person on January 27, 2022, pursuant to a grant under the Plan. The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2023; (ii) January 27, 2024; and (iii) January 27, 2025.
- [F4]Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock.
- [F5]The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 27, 2021, under the Plan. The remaining RSUs vest in equal portions on: (i) January 27, 2023; and (ii) January 27, 2024.
- [F6]The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 29, 2020, under the Plan. The remaining RSUs vest on January 29, 2023.
- [F7]The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 31, 2019, under the Issuer's 2011 Equity Incentive Plan, as amended.
Documents
Issuer
BIODELIVERY SCIENCES INTERNATIONAL INC
CIK 0001103021
Entity typeother
Related Parties
1- filerCIK 0001748462
Filing Metadata
- Form type
- 4
- Filed
- Jan 30, 7:00 PM ET
- Accepted
- Jan 31, 5:58 PM ET
- Size
- 19.3 KB